FMP

FMP

Enter

ARPO - Aerpio Pharmace...

photo-url-https://financialmodelingprep.com/image-stock/ARPO.jpg

Aerpio Pharmaceuticals, Inc.

ARPO

NASDAQ

Inactive Equity

Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The company is headquartered in Blue Ash, Ohio and currently employs 27 full-time employees. The firm is focused on developing treatments for ocular disease. Its lead product candidate is AKB-9778. Its other two pipeline programs include AKB-4924 and ARP-1536. AKB-9778 is a small molecule activator of the Tie-2 pathway, which is being developed for the treatment of diabetic retinopathy (DR). AKB-4924 is a selective stabilizer of hypoxia-inducible factor-1 alpha (HIF-1alpha), which is being developed for the treatment of inflammatory bowel disease (IBD). ARP-1536 is a humanized monoclonal antibody directed at the same target as AKB-9778. ARP-1536 binds the extracellular domain of vascular endothelial protein tyrosine phosphatase (VE-PTP) inhibiting its ability to interact with Tie-2. As of April 14, 2017, the Company had completed a Phase II trial of AKB-9778 in 144 patients with diabetic macular edema. As of April 14, 2017, the Company had completed Phase Ia clinical trial in healthy volunteers for AKB-4924.

2.2 USD

-0.01999998 (-0.909%)

About

ceo

N/A

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The company is headquartered in Blue Ash, Ohio and currently employs 27 full-time employees. The firm is focused on developing treatments for ocular disease. Its lead product candidate is AKB-9778. Its other two pipeline programs include AKB-4924 and ARP-1536. AKB-9778 is a small molecule activator of the Tie-2 pathway, which is being developed for the treatment of diabetic retinopathy (DR). AKB-4924 is a selective stabilizer of hypoxia-inducible factor-1 alpha (HIF-1alpha), which is being developed for the treatment of inflammatory bowel disease (IBD)....

CIK

0001422142

ISIN

US00810B1052

CUSIP

00810B105

Address

9987 Carver Rd

Phone

15139851920

Country

US

Employee

12

IPO Date

Jun 26, 2018

ARPO Financial Summary

CIK

0001422142

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

00810B105

ISIN

US00810B1052

Country

US

Price

2.2

Beta

1.65

Volume Avg.

401.78k

Market Cap

53.67M

Shares

-

52-Week

2.16-2.3

DCF

3.21

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

0

P/B

-

Website

http://www.aerpio.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest ARPO News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep